Jeffrey Conn

In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials.     Read More

Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications. Read More

Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported. Read More

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia. Read More

Eight current faculty members at Vanderbilt have made this year’s list of scientists whose papers have been cited most frequently by other researchers. Read More

P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health. Read More

Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice. Read More

A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder. Read More

Five current faculty members at Vanderbilt University Medical Center have made this year’s list of scientists whose papers have been cited most frequently by others. Read More

Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans. Read More

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness. Read More

Vanderbilt University’s P. Jeffrey Conn, Ph.D., has won a Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders and Stroke for discoveries that could lead to new treatments for anxiety, schizophrenia and other brain disorders. Read More

Heidi Hamm, Ph.D. In their introductions of Heidi Hamm, Ph.D., prior to her Flexner Discovery Lecture last week, Susan Wente, Ph.D., and P. Jeffrey Conn, Ph.D., recounted how early encounters with her influenced their careers. For Wente, associate vice chancellor for… Read More

Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease. Read More

AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia. Read More

Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners. Read More

Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease. Read More

When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects. Read More

Vanderbilt University has emerged as one of the nation’s leading academic centers in neuroscience. Read More

With the addition of a new 18,000-square-foot laboratory to be located within the Cool Springs Life Sciences Center, Vanderbilt University is expanding its research enterprise into Williamson County. Read More